Ser136
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser136  -  HSF1 (human)

Site Information
DIKIRQDsVTKLLtD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 38489569
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , gastric cancer ( 3 ) , lung cancer ( 2 ) , small-cell lung cancer ( 2 )
Relevant cell line - cell type - tissue:
breast ( 1 ) , DMS79 (pulmonary) ( 2 ) , lung ( 2 ) , MKN-45 (gastric) ( 3 ) , NCI-H128 (pulmonary) ( 2 ) , NCI-H1417 (pulmonary) ( 2 ) , NCI-H209 (pulmonary) ( 2 ) , NCI-H524 (pulmonary) ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K (2012) CST Curation Set: 16149; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS*/T*) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759
Curated Info